Development of a Doxazosin and Finasteride Transdermal System for Combination Therapy of Benign Prostatic Hyperplasia-Reference-Cited by-同舟云学术

Development of a Doxazosin and Finasteride Transdermal System for Combination Therapy of Benign Prostatic Hyperplasia

Published:2013-11 Issue:11 Volume:102 Page:4057-4064
ISSN:0022-3549
Container-title:Journal of Pharmaceutical Sciences
language:en
Short-container-title:Journal of Pharmaceutical Sciences

Author:

Pupe Carolina Gonçalves,Do Carmo Flávia Almada,De Sousa Valéria Pereira,Lopes Marlene,Abrahim-Vieira Bárbara,Ribeiro António José,Veiga Francisco,Rodrigues Carlos Rangel,Padula Cristina,Santi Patrizia,Cabral Lucio Mendes

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference27 articles.

1. Prostate stem cells and benign prostatic hyperplasia;Isaacs;Prostate,2008

2. Prevalence of lower urinary tract symptoms and self-reported diagnosed ‘benign prostatic hyperplasia’, and their effect on quality of life in a community-based surrey of men in the UK;Trueman;BJU Int,1999

3. Urological disorders in men: Urinary incontinence and benign prostatic hyperplasia;Miller;J Pharm Pract,2011

4. Established medical therapy for benign prostatic hyperplasia;Auffenberg;Urol Clin North Am,2009

5. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia;McConnell;N Engl J Med,2003

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanical, optical, and physicochemical properties of HPMC-based doxazosin mesylate orodispersible films;Brazilian Journal of Pharmaceutical Sciences;2023

2. Optimization, characterization and in vivo evaluation of mupirocin nanocrystals for topical administration;European Journal of Pharmaceutical Sciences;2022-09

3. Hydrogels as promising therapeutic strategy for the treatment of skin cancer;Journal of Molecular Structure;2022-08

4. Preparation and evaluation of red propolis and nystatin cyclodextrin inclusion complexes against oral microbiome opportunistic microorganisms;Food Science and Technology;2022

5. Development of rivaroxaban microemulsion-based hydrogel for transdermal treatment and prevention of venous thromboembolism;Colloids and Surfaces B: Biointerfaces;2021-10